New application of beta-anhydroicaritin
By using β-dehydrated icariin to promote T cell activation and kill tumor cells, the problem of poor treatment effect of colorectal cancer and the application challenges of traditional Chinese medicine monomer compounds in the prior art is solved, and effective prevention of colorectal cancer is achieved and treatment, have high clinical application value.
Patent Information
- Application Number
- CN202411224553.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-29
AI Technical Summary
The five-year survival rate of existing colorectal cancer treatment methods has not been significantly improved, and the application of Chinese medicine monomer compounds in tumor treatment faces the problems of complex extraction, low bioavailability and insufficient clinical research, and lack of effective new drug development plans.
Use β-Anhydrocaritin as the drug-active ingredient to prepare drugs for preventing and treating tumors, including but not limited to colorectal Cancer, and no obvious toxic side effects.
β-dehydrated icariin significantly promotes T cell activation, releases cytokines such as IFN-γ, TNF-α, Granzyme B, etc., effectively inhibits tumor cell growth, reduces tumor volume and weight, and has potential clinical application prospects and high economic value.
Smart Images

Figure CN119033761A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to the application of beta-anhydroicariin in preparing medicines for preventing and / or treating tumors. Background Art
[0002] Colorectal cancer (CRC) is the third most common cancer in the world, with a higher incidence in both men and women. According to the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), there are more than 1.8 million newly diagnosed cases of colorectal cancer and about 880,000 deaths each year. The occurrence of colorectal cancer is related to a variety of factors, including eating habits, lifestyle, genetic factors, etc. Its early symptoms are usually not obvious, including blood in the stool, abdominal pain, and changes in bowel habits, which also causes many patients to be in the late stage of cancer when diagnosed.
[0003] Cancer immunotherapy is a major breakthrough in the field of tumor treatment in recent years. It identifies and eliminates cancer cells by activating or enhancing the patient's own immune system. Compared with traditional cancer treatment methods, immunotherapy has many unique advantages, such as the ability to specifically identify and attack cancer cells and less damage to normal cells. Although traditional chemotherapy and radiotherapy can kill cancer cells, they can also damage normal cells and cause serious side effects. In addition, the immune system also has a memory function. After being activated by immunotherapy, it can remember the characteristics of cancer cells for a long time and respond quickly when cancer cells appear again. This long-lasting immune surveillance function helps reduce the risk of cancer recurrence. At the same time, immunotherapy can be used in combination with other treatments such as chemotherapy, radiotherapy, targeted therapy, etc. to enhance the overall treatment effect.
[0004] At present, the treatment methods for colorectal cancer include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. However, in clinical practice, the five-year survival rate of colorectal cancer has not been significantly improved. Monomer compounds of traditional Chinese medicine are single chemical components extracted and purified from traditional Chinese medicinal materials, usually with clear chemical structures and biological activities. In the process of research on traditional Chinese medicine and its integration with modern medicine, monomer compounds of traditional Chinese medicine have become an important part of pharmacological research, drug development and disease treatment. Monomer compounds of traditional Chinese medicine have a variety of pharmacological effects, which are usually closely related to their chemical structures. For example, curcumin (extracted from turmeric) exerts anti-inflammatory effects by inhibiting the release of inflammatory mediators, baicalein (extracted from scutellaria baicalensis) has an inhibitory effect on a variety of viruses, and berberine has an inhibitory effect on a variety of bacteria and is often used to treat gastrointestinal infections. In recent years, some studies have also shown that monomer compounds of traditional Chinese medicine can play an important role in anti-tumor, such as triptolide A, which plays a role by inducing tumor cell apoptosis, inhibiting cell proliferation and metastasis. However, the research and application of monomer compounds of traditional Chinese medicine also face some challenges, including overly complex extraction and purification operations, low bioavailability, and insufficient clinical research. However, with the advancement of modern science and technology and the deepening of traditional Chinese medicine research, the application prospects of traditional Chinese medicine monomer compounds in drug development and clinical treatment are relatively broad.
[0005] Chinese patent application CN112494467A (Zhejiang University) discloses the use of Chinese medicine monomer compound vanillin in the preparation of nicotinamide-N-methyltransferase inhibitors. Studies have shown that vanillin can reduce the resistance of colorectal cancer cell lines to 5-FU caused by high expression of NNMT in vitro and enhance chemotherapy sensitivity. It can also induce apoptosis of colorectal cancer cell lines with high expression of NNMT by inducing intracellular ROS production and mitochondrial damage. At the same time, it can also enhance the inhibitory effect of 5-fluorouracil on tumor proliferation and enhance the chemotherapy effect. It can be used as an NNMT inhibitor to prepare drugs or adjuvant chemotherapy drugs for the treatment of colorectal cancer. In addition, Chinese patent application CN115813903A (Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine) discloses the use of Chinese medicine monomer compound baicalin in the preparation of drugs for the treatment of diseases related to targeted ProDH reversal of 5-Fu resistance. Studies have shown that baicalin combined with 5-Fu can significantly inhibit the proliferation of human colorectal cancer cell lines and human colorectal cancer 5-Fu resistant cell lines and promote cell apoptosis. Chinese patent application CN110201017A requests protection for the use of the Chinese medicine monomer compound Panax notoginseng total saponins combined with Tanshinone ⅡA in the preparation of drugs for preventing colorectal cancer. Studies have shown that the combination of the two can effectively prevent the occurrence of inflammatory colorectal cancer in mice. Chinese patent application CN105963637B (Sun Yat-sen University) protects the use of the Chinese medicine monomer compound cryptotanshinone combined with curcumin in the preparation of drugs for preventing and treating tumors (especially colorectal cancer and leukemia). By quantitatively combining Chinese medicine monomers with different anti-cancer mechanisms and assisting in enhancing their effectiveness, more tumor cells can be killed while reducing the drug concentration. In summary, screening and developing new Chinese medicine monomer compounds that can be used to treat colorectal cancer will have potential clinical application prospects. Summary of the invention
[0006] The main technical problem solved by the present invention is to provide a new medicine for preventing and treating colorectal cancer, comprising a pharmaceutically effective amount of β-anhydroicariin.
[0007] Meanwhile, the invention provides a new use of beta-anhydroicariin.
[0008] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0009] The invention relates to a new use of β-anhydroicariin, specifically, use of β-anhydroicariin in the preparation of drugs for preventing and / or treating tumors.
[0010] The English name of β-anhydroicaritin: β-Anhydroicaritin, molecular formula: C 21 H 20 O6, molecular weight: 368.38, CAS number: 38226-86-7, chemical structure is as follows:
[0011]
[0012] As a preferred embodiment of the present invention, the application includes but is not limited to one or more of the following aspects:
[0013] (1) Application of β-anhydroicariin in the preparation of drugs for promoting T cell proliferation;
[0014] (2) Application of β-anhydroicariin in the preparation of drugs for promoting T cells to release cytokines;
[0015] (3) Application of β-anhydroicariin in the preparation of drugs that promote T cells to kill tumor cells.
[0016] Specifically, the cytokines include but are not limited to IFN-γ, TNF-α, Granzyme B, etc.
[0017] Specifically, the tumor cells include but are not limited to colorectal cancer, endometrial cancer, hepatocellular carcinoma, pancreatic cancer, lung adenocarcinoma, esophageal cancer, breast cancer, low-grade glioma, renal papillary cell carcinoma, nodal parisha myofibroblastoma, neuromuscular aberrant tumor, desmoid tumor, juvenile angiofibroma, enamel-type craniopharyngiocarcinoma, hepatoblastoma, pancreatic ductal carcinoma, biliary tract cancer, cerebral hemangioma, skin Merkel cell carcinoma, skin squamous cell carcinoma, melanoma in situ, skin basal cell carcinoma, etc.
[0018] As a preferred embodiment of the present invention, the application includes but is not limited to one or more of the following aspects:
[0019] (1) Application of β-anhydroicariin in the preparation of drugs for promoting immune cell infiltration into tumor tissues;
[0020] (2) Application of β-anhydroicariin in the preparation of drugs for inhibiting tumor growth.
[0021] Specifically, the immune cell infiltration into tumor tissue includes but is not limited to increasing the proportion of CD8 positive T cells in tumor tissue.
[0022] Specifically, the inhibition of tumor growth includes but is not limited to reducing tumor volume, reducing tumor weight, etc.
[0023] Specifically, the tumors include but are not limited to colorectal cancer, endometrial cancer, hepatocellular carcinoma, pancreatic cancer, lung adenocarcinoma, esophageal cancer, breast cancer, low-grade glioma, renal papillary cell carcinoma, nodal parisha myofibroblastoma, neuromuscular aberrant tumor, desmoid tumor, juvenile angiofibroma, enamel-type craniopharyngiocarcinoma, hepatoblastoma, pancreatic ductal carcinoma, biliary tract cancer, cerebral hemangioma, skin Merkel cell carcinoma, skin squamous cell carcinoma, melanoma in situ, skin basal cell carcinoma, etc.
[0024] A medicine for preventing and / or treating tumors, wherein the effective ingredients of the medicine include beta-anhydroicariin.
[0025] As a preferred embodiment of the present invention, the content of β-anhydroicariin in the drug is an effective amount, which can be in the range of 0.01wt%-99.99wt%.
[0026] As a preferred embodiment of the present invention, the drug further comprises other medicinal ingredients, including but not limited to other anti-tumor or auxiliary anti-tumor medicinal ingredients, for combined therapy or auxiliary therapy.
[0027] As a preferred embodiment of the present invention, the drug further comprises a pharmaceutically acceptable carrier, including but not limited to solvents, excipients, preservatives, stabilizers, emulsifiers, salts for adjusting osmotic pressure, buffers, and the like.
[0028] As a preferred embodiment of the present invention, the dosage form of the drug is a pharmaceutically acceptable dosage form, including but not limited to powder injection, injection solution, tablet, pill, capsule, spray, dispersion and the like.
[0029] As a preferred embodiment of the present invention, the administration route of the drug is a pharmaceutically acceptable route, including but not limited to oral, intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, and transdermal, intranasal or oral inhalation.
[0030] As a preferred embodiment of the present invention, the dosage of the drug is a pharmaceutically acceptable dosage.
[0031] Beneficial effects of the present invention:
[0032] The present invention constructs an MC38 colorectal cancer cell line expressing the model antigen OVA, and expresses OVA under the presentation of the major histocompatibility complex H2b molecule. 257-264 Model peptides were isolated to specifically recognize OVA 257-264The OT-1T cells with the model peptides were cultured and induced to activate, and the OT-1T cells, MC38-OVA and different Chinese medicine monomer compounds were co-cultured, and the Chinese medicine monomer compounds that can effectively promote the anti-tumor activity of OT-1T cells were obtained by high-content screening technology. The present invention screened out 6 Chinese medicine monomer compounds that can activate the anti-tumor activity of T cells from a library containing 1280 Chinese medicine monomer compounds. After repeated verification, it was finally determined that β-anhydroicaritin was used as the research object to carry out in vitro and in vivo anti-tumor activity experiments. The results showed that β-anhydroicaritin can significantly promote T cell activation, release cytokines such as IFN-γ, TNF-α, Granzyme B, and promote the killing effect on tumor cells. At the same time, in vivo experiments in mice also showed that β-anhydroicaritin can inhibit the growth of colorectal tumor cells, reduce tumor volume, reduce tumor weight, and have no obvious toxic side effects. It has high safety and can be used to prepare drugs for preventing and treating tumors, and has potential clinical application prospects and high economic value.
[0033] The drug for preventing and / or treating tumors provided by the present invention comprises a pharmaceutically effective amount of β-anhydroicariin and a pharmaceutically acceptable carrier or excipient, and can be prepared into a drug dosage form that is convenient for clinical use and can exert the best therapeutic effect, and has certain pharmaceutical prospects and commercial value. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 These are the in vitro experimental results in the experimental examples.
[0035] Figure 2 These are the in vivo experimental results in the experimental examples.
[0036] The significance analysis symbols in the accompanying drawings are: ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001.
[0037] In order to more clearly illustrate the technical solution to be protected by the present invention, the drawings in the embodiments or experimental examples are briefly introduced above. It should be understood that the above drawings should not be regarded as any limitation on the protection scope of the present invention. For ordinary technicians in this field, other related drawings can also be obtained based on these drawings without paying creative work. DETAILED DESCRIPTION
[0038] The technical solution of the present invention will be clearly and completely explained below in conjunction with specific embodiments and experimental examples.
[0039] Those skilled in the art should understand that the following embodiments and experimental examples are only used to illustrate the technical solutions and technical effects of the present invention and should not be regarded as any limitation on the protection scope of the present invention. Based on the following embodiments, other technical solutions obtained by those skilled in the art without creative work, such as technical solutions obtained after modification, deformation or simple replacement, all belong to the protection scope of the present invention.
[0040] Unless otherwise specified, the raw materials, reagents, and equipment used in the examples or experimental examples are all commercially available products.
[0041] Example 1
[0042] This embodiment provides a new use of β-anhydroicariin, specifically: use of β-anhydroicariin in the preparation of a drug for preventing and / or treating tumors.
[0043] The English name of β-anhydroicaritin: β-Anhydroicaritin, molecular formula: C 21 H 20 O6, molecular weight: 368.38, CAS number: 38226-86-7, chemical structure is as follows:
[0044]
[0045] Example 2
[0046] This embodiment provides a new use of β-anhydroicariin, including but not limited to one or more of the following aspects:
[0047] (1) Application of β-anhydroicariin in the preparation of drugs for promoting T cell proliferation;
[0048] (2) Application of β-anhydroicariin in the preparation of drugs for promoting T cells to release cytokines such as IFN-γ, TNF-α, and Granzyme B;
[0049] (3) Application of β-anhydroicariin in the preparation of drugs that promote T cells to kill tumor cells.
[0050] Example 3
[0051] This embodiment provides a new use of β-anhydroicariin, including but not limited to one or more of the following aspects:
[0052] (1) Use of β-anhydroicariin in the preparation of a drug for promoting immune cell infiltration into tumor tissue, such as increasing the proportion of CD8 positive T cells in tumor tissue;
[0053] (2) Use of β-anhydroicariin in the preparation of drugs for inhibiting tumor growth, such as reducing tumor volume and reducing tumor weight.
[0054] Example 4
[0055] This embodiment provides a drug for preventing and / or treating colorectal cancer, comprising a pharmaceutically effective amount of β-anhydroicariin, and a pharmaceutically acceptable oil-soluble solvent, stabilizer and preservative, for preparing the drug into an injection dosage form.
[0056] In other embodiments of the present invention, the drug also includes other medicinal ingredients for combined treatment or adjuvant treatment of colorectal cancer.
[0057] In other embodiments of the present invention, the dosage form of the drug is other pharmaceutically acceptable dosage forms, such as capsules, tablets, etc., which contain other pharmaceutically acceptable carriers.
[0058] In other embodiments of the present invention, the dosage of the drug is a pharmaceutically acceptable dosage, and the usage and dosage of the drug needs to be determined according to the condition of the disease and can be followed according to the doctor's advice.
[0059] Experimental example
[0060] 1. Screening of Monomer Compounds of Traditional Chinese Medicine
[0061] First, construct overexpression of OVA 257-264 The MC38-OVA-GFP cell line with the model peptide was screened at 2μM for 1280 Chinese medicine monomer compounds, and 42 Chinese medicine monomer compounds were screened out to have obvious inhibitory or lethal effects on the growth of the MC38 cell line. These 42 compounds were subsequently excluded. 257-264 The OT-1T cells with the model peptide were activated and induced. A second screening was performed under the co-culture conditions of MC38-OVA and OT-1T cells, and 6 Chinese medicine monomer compounds were screened out to promote T cells to kill tumor cells. After repeated verification, the Chinese medicine monomer compound β-anhydroicariin was finally selected, which can significantly promote T cells to kill tumor cells at a concentration of 2μM and has no effect on tumor cell growth.
[0062] 2. In vitro experiments
[0063] 1. Flow cytometry was used to detect cell death after co-culture. The method is as follows:
[0064] (1) MC38-OVA cells in good condition and in the logarithmic growth phase were digested and counted, with a concentration of 2×10 5 The cells were seeded into 6-well plates at a density of 10 cells / well, and then OT-1 mice activated with anti-mouse CD3\CD28 and IL-2 were added. +T cells, and ensure that MC38-OVA: T cells = 0.3:1, β-anhydroicariin was added to the experimental group wells to make its working concentration 2 μM, and the same volume of DMSO was added to the control group wells.
[0065] (2) After 48 hours of co-culture, photos were taken under a microscope.
[0066] (3) Digest the cells with EDTA-free trypsin, wash the cells three times with pre-cooled PBS, centrifuge at 4°C, 800 rpm for 5 min, and discard the PBS after centrifugation.
[0067] (4) Staining: Add PI (propidium iodide) to a final concentration of 50 μg / mL, incubate at room temperature in the dark for 10 min (10-15 min is acceptable), and then place on ice.
[0068] (5) Flow cytometry was used for detection, and then FlowJo was used for data processing and GraphPad was used for statistical drawing. Figure 1 shown.
[0069] Experimental results: When tumor cells and T cells were co-cultured with β-anhydroicariin, flow cytometry was used to detect the death of tumor cells. Figure 1 As shown in A, when there is no drug treatment, OT-1T cells can kill about 20% of tumor cells, and after adding β-anhydroicariin for 48 hours, the killing ratio reaches 80%. It can be seen that β-anhydroicariin can significantly promote T cells to kill tumor cells.
[0070] At the same time, in order to exclude the influence of the parent ring "benzopyran ring" structure of β-anhydroicariin on T cells, other compounds with the same parent ring structure were used as controls. The experimental results are as follows Figure 1 As shown in B. It can be seen from the figure that compared with other compounds, the effect of β-anhydroicariin in promoting T cells to kill tumor cells is specific.
[0071] 2. Clone formation experiment, the method is as follows:
[0072] (1) MC38 cells in good condition and in the logarithmic growth phase were digested and counted, and seeded into a 6-well plate at a density of 1000 cells / well. β-anhydroicariin was added to the experimental wells to make its working concentration 2 μM, and the same volume of DMSO was added to the control wells.
[0073] (2) After 10 days of growth, discard the culture supernatant in the wells and wash three times with PBS.
[0074] (3) Add 1 mL of 4% paraformaldehyde and fix at room temperature for 20 min.
[0075] (4) Wash the paraformaldehyde with PBS, add crystal violet solution, and stain at room temperature for 5 minutes.
[0076] (5) Use PBS to clean the crystal violet, then use a scanner to take pictures, use ImageJ to count the number of clones, and use GraphPad to make a graph. The results are as follows Figure 1 shown.
[0077] Experimental results: The clone formation experiment was carried out to detect the effect of β-anhydroicariin on tumor cell proliferation. Figure 1 As shown in C, compared with the control group, the number of clones formed by the MC38-OVA cell line after being treated with 2 μM β-anhydroicariin did not change significantly, indicating that β-anhydroicariin itself does not affect the proliferation of tumor cells.
[0078] 3. CFSE was used to detect T cell proliferation as follows:
[0079] (1) Isolation of CD8 + After T cells were stimulated, 0.5 μg / mL anti-mouse CD3, 0.5 μg / mL anti-mouse CD28 and 100 ng / mL mouse IL-2 were added to activate T cells; at the same time, some T cells were added with only 100 ng / mL mouse IL-2 as the stimulation group.
[0080] (2) After T cell activation for 48 hours, the cells were collected in a 15 mL centrifuge tube and centrifuged at 2000 rpm for 5 min.
[0081] (3) Add CFSE labeling solution in dark place and incubate at 37°C in dark place for 10 min. Immediately add about 10 mL of complete cell culture medium (containing serum) into a 15 mL centrifuge tube, mix by inversion several times at room temperature, and centrifuge at 2000 rpm for 5 min.
[0082] (4) Add 10 mL (5-10 mL) of complete cell culture medium and incubate at 37°C for 5 min to promote the retention of CFDA SE in the cells and the entry of unreacted CFDA SE into the complete cell culture medium.
[0083] (5) Wash the cells twice with complete medium, then add β-anhydroicariin at a final concentration of 2 μM and place them in an incubator in the dark for 5 days. Figure 1 shown.
[0084] Experimental results: Flow cytometry was used to detect the proliferation of T cells after adding 2 μM β-anhydroicariin. Figure 1 As shown in D, the addition of 2 μM β-anhydroicariin treatment can significantly promote the proliferation of T cells.
[0085] 4. Flow cytometry detection of CD8 + T cell intracellular factors, the method is as follows:
[0086] (1) CD8 + The T cell density was adjusted to 1 × 10 6 cell / mL.
[0087] (2) After adding 0.5 μg / mL anti-mouse CD3, 0.5 μg / mL anti-mouse CD28 and 100 ng / mL mouse IL-2 to activate T cells, β-anhydroicariin was added to make the final concentration of 2 μM, and the drug treatment was carried out for 48 hours.
[0088] (3) Add a protein transport inhibitor to each well to a final concentration of 1 μg / mL and place the well in an incubator for another 4 hours.
[0089] (4) Surface antibody staining: Collect cells and add anti-mouse CD8 BV605 to the tube, incubate on ice in the dark for 30 min, add 1 mL of PBS after incubation, and centrifuge at 2000 rpm for 5 min.
[0090] (5) Fixation and membrane permeabilization: After centrifugation, add 200 μL of fixative to the tube and fix at room temperature for 30 min. Then add 800 μL of membrane permeabilization agent and permeabilize at room temperature for 5 min. After membrane permeabilization, centrifuge at 2000 rpm for 5 min.
[0091] (6) For intracellular factor staining, IFN-γ, TNF-α, and Granzyme B antibodies were diluted with a membrane permeabilization reagent and added to the fixed and permeabilized cells and incubated on ice for 30 min.
[0092] (7) Flow cytometry. The results are as follows Figure 1 shown.
[0093] Experimental results: When T cells were treated with β-anhydroicariin for 48 hours, IFN-γ was detected by flow cytometry. + CD8 + TNF-α + CD8 + 、Granzyme B + CD8 + Ratio. Figure 1 As shown in E, β-anhydroicariin treatment can significantly promote the release of IFN-γ, TNF-α and Granzyme B by T cells.
[0094] 3. In vivo experiments
[0095] 1. Mouse tumor-bearing experiment, the method is as follows:
[0096] (1) MC38 cells that are in good growth condition and in the logarithmic growth phase were digested and washed three times with pre-cooled PBS, centrifuged at 800 rpm and 4°C for 5 min each time, and the cells were counted and diluted to 2×10 with pre-cooled PBS. 6 The density of each was 100 μL / 200 μL and placed on ice for later use.
[0097] (2) Ten 6-week-old C57BL / 6 male mice were subcutaneously loaded with tumors and the cells were inoculated with 200 μL / mouse / 2×10 6 The number of cells was used for subcutaneous tumor implantation.
[0098] (3) When the tumor grows to about 40-50 mm 3 The mice were randomly divided into two groups, 5 mice in each group. The experimental group was intraperitoneally injected with 10 mg / kg of β-anhydroicariin every day. The injection liquid was a mixture of β-anhydroicariin and corn oil. The control group was intraperitoneally injected with a mixture of DMSO and corn oil in the same volume and ratio. The first day of intraperitoneal injection was recorded as day 0 (i.e., D0). The weight of the mice and the mouse tumors were measured and counted every two days. The drug was administered continuously for 14 days. On the 15th day (i.e., D14), the mouse tumors were dissected and the tumor size and weight were measured, photographed, and the tumor inhibition rate was counted (the formula is as follows). The results are shown in Figure 2 shown.
[0099] Tumor inhibition rate = (1-tumor weight of experimental group / tumor weight of control group) × 100%.
[0100] (4) The hearts, livers, spleens, lungs, and kidneys of the mice in the experimental and control groups were fixed in 4% paraformaldehyde. The tumors of the mice in the experimental and control groups were fixed in 4% paraformaldehyde and sent to a paraffin embedding company for paraffin embedding.
[0101] (5) Paraffin sectioning: Use a paraffin slicer to slice the tissue wax block to a thickness of 6 μm, and attach it to a glass slide. Mark the sample and set aside.
[0102] 2. HE staining experiment, the method is as follows:
[0103] (1) Dewaxing: Place paraffin tissue sections in xylene I and II for 10 min each, and then in anhydrous ethanol, 90% ethanol, 80% ethanol, 70% ethanol, and 50% ethanol for 5 min each, for gradient dewaxing.
[0104] (2) Wash the dewaxed tissue sections in water, wipe off the water on the sections, stain with hematoxylin for 5 minutes, wash with running water, stain with eosin for 1 minute, wash with running water, and then put the paraffin sections into 75% ethanol for 2 minutes, 85% ethanol for 2 minutes, anhydrous ethanol for 5 minutes, anhydrous ethanol for 5 minutes, and xylene for 5 minutes in sequence for transparent treatment, wash the sections, seal with cedar oil, and perform full-wave plate scanning using the intelligent pathology imaging analysis system. The results are as follows Figure 2 shown.
[0105] 3. Immunofluorescence staining of paraffin sections, the method is as follows:
[0106] (1) Wash the dewaxed tissue sections in water.
[0107] (2) Antigen repair: Use EDTA antigen repair solution to repair the slices in a boiling water bath for 20 minutes, then let them cool naturally and wash them with PBS three times, each time for 5 minutes; use an immunohistochemistry pen to draw a circle around the tissue to facilitate the addition of various reagents.
[0108] (3) Permeabilization: Permeabilize with PBS containing 0.2% TritonX-100 at room temperature for 20 min, and wash with PBS three times, each time for 5 min.
[0109] (4) Blocking: Block with PBS containing 10% goat serum and 0.01% TritonX-100 at room temperature for 30 min, and wash with PBS three times, each time for 5 min.
[0110] (5) Antibody incubation: Add the diluted anti-mouse CD8 antibody at a ratio of 1:300 onto the tissue, incubate at 4°C overnight, and then wash three times with PBS, each time for 5 min.
[0111] (6) DAPI was diluted with PBS at a ratio of 1:20, then incubated at room temperature for 1 h, washed with PBS 3 times, 5 min each time, and then sealed with cedar oil and scanned using the intelligent pathology imaging analysis system. Figure 2 shown.
[0112] 4. Experimental results
[0113] The colorectal cancer cell line MC38 was used to conduct a subcutaneous tumor-bearing experiment in mice. After the mice developed tumors, they were randomly divided into two groups. The experimental group mice were intraperitoneally injected with β-anhydroicariin every day, and the control group mice were injected with the same amount of DMSO and corn oil mixture. Figure 2 As shown in A-2D, the tumors of mice in the experimental group were significantly smaller than those in the control group, and both the tumor volume and weight were significantly reduced. The average inhibition rate of β-anhydroicariin on mouse tumors was 59.89%. Figure 2D is a statistical graph of mouse tumor volume. The tumor volume was counted every two days. It can be seen from the graph that the growth trend of the tumor in the experimental group of mice after administration was slower than that in the control group, and the tumor volume of the mice in the experimental group was inhibited in the later period. After the mouse tumor was fixed, paraffin tissue sections were made and immunofluorescence staining was performed, such as Figure 2 As shown in E, the proportion of CD8 positive cells in the experimental group increased significantly. At the same time, paraffin tissue sections of the heart, liver, spleen, lung, and kidney of the mice were sliced and HE staining was performed to evaluate the safety of β-anhydroicariin. Figure 2 As shown in F, there was no significant difference in HE staining of the heart, liver, spleen, lung, and kidney of mice between the experimental group and the control group, indicating that β-anhydroicariin had no obvious toxic side effects.
[0114] 4. Experimental Conclusion
[0115] The present invention screened out β-dehydrated icariin by co-culturing OT-1 mouse T cells with MC38-OVA, which can significantly promote T cells to kill colon cancer cells MC38. Then, MC38 was treated with β-dehydrated icariin alone, and it was found that the drug did not directly act on tumor cells. Next, T cells were treated with β-dehydrated icariin alone, and the CFSE experimental results showed that β-dehydrated icariin can promote T cell proliferation. At the same time, intracellular factor staining experiments proved that β-dehydrated icariin can promote the release of IFN-γ, TNF-α, and Granzyme B.
[0116] Finally, in vivo experiments in mice were designed to verify the anti-tumor activity. Subcutaneous tumor-bearing experiments were performed using the MC38 cell line, and mice were intraperitoneally injected with β-dehydroicariin. The tumor volume of the mice was measured and calculated and statistically analyzed. The tumor tissue was stained with HE and CD8 immunofluorescence staining, which proved that β-dehydroicariin could promote the infiltration of immune cells and significantly inhibit the growth of mouse tumors. It is safe and can be used to prepare drugs to prevent tumors. It has potential clinical application value and high economic value.
[0117] Although the technical solution of the present invention has been described in detail above with general descriptions, specific implementation methods and experimental examples, it should be noted that the embodiments and experimental examples are only used to illustrate the technical solution and technical effects of the present invention, and should not be regarded as any limitation on the protection scope of the present invention. Simple deformation, modification or improvement based on the technical concept of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A new use of β-anhydroicariin, characterized in that: Application of beta-anhydroicariin in preparing medicine for preventing and / or treating tumors.
2. The novel use according to claim 1, characterized in that: The application includes but is not limited to one or more of the following aspects: (1) Application of β-anhydroicariin in the preparation of drugs for promoting T cell proliferation; (2) Application of β-anhydroicariin in the preparation of drugs for promoting T cells to release cytokines; (3) Application of β-anhydroicariin in the preparation of drugs that promote T cells to kill tumor cells.
3. The new use according to claim 2, characterized in that: The cytokines include but are not limited to IFN-γ, TNF-α, Granzyme B; And / or, tumor cells include but are not limited to colorectal cancer, endometrial cancer, hepatocellular carcinoma, pancreatic cancer, lung adenocarcinoma, esophageal cancer, breast cancer, low-grade glioma, renal papillary cell carcinoma, nodal parisha myofibroblastoma, neuromuscular aberrant tumor, desmoid tumor, juvenile angiofibroma, enamel-type craniopharyngiocarcinoma, hepatoblastoma, pancreatic ductal carcinoma, biliary tract cancer, cerebral hemangioma, skin Merkel cell carcinoma, skin squamous cell carcinoma, melanoma in situ, skin basal cell carcinoma.
4. The new use according to claim 1, characterized in that: The application includes but is not limited to one or more of the following aspects: (1) Application of β-anhydroicariin in the preparation of drugs for promoting immune cell infiltration into tumor tissues; (2) Application of β-anhydroicariin in the preparation of drugs for inhibiting tumor growth.
5. The new use according to claim 4, characterized in that: The immune cell infiltration into tumor tissue includes but is not limited to increasing the proportion of CD8 positive T cells in tumor tissue; And / or, the inhibition of tumor growth includes but is not limited to reducing tumor volume and reducing tumor weight; And / or, the tumor includes but is not limited to colorectal cancer, endometrial cancer, hepatocellular carcinoma, pancreatic cancer, lung adenocarcinoma, esophageal cancer, breast cancer, low-grade brain glioma, renal papillary cell carcinoma, nodal parisha myofibroblastoma, neuromuscular aberrant tumor, desmoid tumor, juvenile angiofibroma, enamel-type craniopharyngiocarcinoma, hepatoblastoma, pancreatic ductal carcinoma, biliary tract cancer, cerebral hemangioma, skin Merkel cell carcinoma, skin squamous cell carcinoma, melanoma in situ, skin basal cell carcinoma.
6. A drug for preventing and / or treating tumors, characterized in that: The active ingredients of the medicine include beta-anhydroicariin.
7. The drug according to claim 6, characterized in that: The content of beta-anhydroicariin in the medicine is the effective amount, which is in the range of 0.01wt%-99.99wt%.
8. The drug according to claim 6, characterized in that: The drug also includes other medicinal ingredients, including but not limited to other anti-tumor or auxiliary anti-tumor medicinal ingredients.
9. The drug according to claim 6, characterized in that: The drug also includes pharmaceutically acceptable carriers, including but not limited to solvents, excipients, preservatives, stabilizers, emulsifiers, salts for adjusting osmotic pressure, and buffers.
10. The drug according to claim 6, characterized in that: The dosage form of the drug is a pharmaceutically acceptable dosage form, including but not limited to powder injection, injection solution, tablet, pill, capsule, spray, and dispersion.
